Iselin NJ, November 3, 2005 – Pharmos Corporation (Nasdaq: PARS) today reported financial results for the third quarter ended September 30, 2005. For the 2005 third quarter the net loss was $3.3 million, or $ 0.17 per share compared to a net loss of $5.9 million, or $ 0.33 per share in the 2004 third quarter. The 45% decrease in net loss was due primarily to […]
Iselin NJ, October 27, 2005 – Pharmos Corporation (Nasdaq: PARS) today announced that it will present at the 7th Annual Rodman & Renshaw Techvest Healthcare Conference on Monday, November 7, 2005 at 9:25 a.m. Eastern Time in the Holmes II room at the Palace Hotel in New York City. Haim Aviv, PH.D., Chairman & CEO, will provide an update on the Company’s business and product pipeline. […]
Iselin NJ, October 17, 2005 – Pharmos Corporation (Nasdaq: PARS) today announced that it will present at the BIO Investor Forum (http://investorforum.bio.org/opencms/bif/2005/index.jsp)on Thursday, October 20, 2005 at 9:40 a.m. Pacific Time in the Sea Cliff room at the Palace Hotel in San Francisco, California. Gad Riesenfeld, Ph.D., President and Chief Operating Officer, will provide an update on the Company’s business and product pipeline. A webcast of […]
Iselin NJ, September 21, 2005 – Pharmos Corporation (Nasdaq: PARS) announced today results of the Company’s Annual Meeting of the Stockholders held yesterday beginning at 11:00 AM ET at the Hilton New York in midtown Manhattan. During the meeting, a quorum was established with votes represented by proxy or meeting attendees amounting to 81% of the 19 million shares outstanding and eligible to be voted, and […]
Iselin NJ, Septemer 6, 2005 – Pharmos Corporation (Nasdaq: PARS) announced today that it has initiated a Phase I trial with cannabinor, a CB2-selective synthetic cannabinoid drug candidate. The study will assess the safety, tolerability and pharmacokinetics of cannabinor in healthy volunteers. The trial will enroll up to 48 healthy male subjects in a randomized, double blind, placebo controlled, intravenous, escalating single dose study. The trial […]
Iselin NJ, July 28, 2005 – Pharmos Corporation (Nasdaq: PARS) today reported financial results for the second quarter ended June 30, 2005. All financial information outlined in this quarterly announcement has been adjusted to reflect the 1 for 5 reverse stock split that was implemented on May 31, 2005. For the 2005 second quarter the net loss was $3.3 million, or $ 0.18 per share compared […]
Proprietary NanoEmulsion Technology: Initial Target to be Treatment of Joint Arthritis Iselin NJ, July 6, 2005 – Pharmos Corporation (Nasdaq: PARS) announced today the initiation of a clinical program to commercialize its proprietary NanoEmulsion drug delivery technology. The Company plans to initiate a Phase I/II feasibility clinical trial before yearend. The study will evaluate safety, pharmacokinetics and the analgesic effect of an approved non-steroidal anti-inflammatory drug […]
Iselin NJ, June 28, 2005 – Pharmos Corporation (Nasdaq: PARS) today announced the appointment of Abraham Sartani, M.D. to a newly created seat on the Company’s Board of Directors. Dr. Sartani, an internationally recognized leader in the pharmaceutical industry, is currently Vice-President and Director, Pharmaceutical Research and Development Division of Recordati S.p.A. Recordati, established in 1926, is a European pharmaceutical group quoted on the Italian Stock […]
Iselin NJ, June 16, 2005 – Pharmos Corporation (Nasdaq: PARSD) today announced that it will present at the BIO 2005 Business Forum on Wednesday, June 22, 2004 at 11:30 am Eastern Time at the Pennsylvania Convention Center in Philadelphia, Pennsylvania. Gad Riesenfeld, Ph.D., President and Chief Operating Officer, will provide an update on the Company’s business and product pipeline. According to the Biotechnology Industry Organization (BIO), […]
Iselin NJ, June 6, 2005 – Iselin, NJ – June 6, 2005 /Business Wire/ — Pharmos Corporation (NasdaqSC: PARSD) will present at the following forum: What: Informed Investors Biotechnology / Healthcare / Pharmaceutical Investor Forum When: June 15, 2005 @ 2:35 PM Eastern Time Sponsors: Barron’s, The Wall Street Journal, The American Stock Exchange and Business Wire Keynote Presentations: Lynn Sutherland, M.S., M.B.A. – […]